InnoCan Pharma

What InnoCan Pharma does

InnoCan Pharma Corporation is a Canadian-incorporated, Israeli-operating pharmaceutical technology company that develops cannabinoid-based drug delivery platforms, primarily targeting non-opioid chronic pain management. The company's core technology is LPT-CBD (Liposome Platform Technology-Cannabidiol), an injectable liposomal CBD formulation designed to provide sustained-release pain relief for up to four weeks per dose. Preclinical and clinical work has progressed in dogs (canine osteoarthritis), goats, and Göttingen Minipigs, with peer-reviewed publications in Frontiers in Veterinary Science and Precision Nanomedicine. A second platform — CBD-loaded exosomes developed in collaboration with ADVA Biotechnology — targets epilepsy, CNS conditions, and additional pain indications. The company is also pursuing a research collaboration with Tel Aviv University on CBD-loaded exosomes for COVID-19.

InnoCan operates two business segments. The Pharmaceuticals segment focuses on LPT-CBD development for both veterinary and human applications, with FDA Center for Veterinary Medicine fee waivers granted in 2024, 2025, and 2026. Patents have been granted or allowed in Japan, India, and Mexico. Revenue from this segment is pre-commercial and currently nil. The Consumer Wellness segment operates through the wholly-owned B.I. Sky Global subsidiary, a microbrands hub selling CBD-based derma-cosmetic, personal care, and beauty products (including the SHIR line distributed in Italy and Switzerland) through e-commerce channels and select distribution partners.

The company generates revenue almost entirely from consumer wellness: FY2024 revenue of US$29.4M declined 9.6% to US$26.6M in FY2025, with Q1 2026 at US$6.47M. Gross margin is unusually high at 89.9%, consistent with branded consumer goods rather than pharmaceutical economics. Operating loss was approximately US$1.26M in FY2025. The company is publicly traded on the Canadian Securities Exchange (INNO), Frankfurt (IP4), and OTC Markets (INNPF), with a deferred NYSE American listing announced for January 2026 but postponed in May 2026 to focus on scaling core operations. The largest shareholder, Tamar Innovest Ltd. (approximately 17% ownership, managed by director Ralph C.L. Bossino), has been the primary source of debt capital via recurring 10% debentures.

Name

InnoCan Pharma

Legal name

Innocan Pharma Corporation

Website

https://innocanpharma.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

InnoCan Pharma is a Canadian-Israeli pharma tech company developing LPT-CBD, a sustained-release liposomal CBD injectable for non-opioid chronic pain in animals and humans, while commercializing CBD wellness and beauty products through its B.I. Sky Global subsidiary.

Ownership category

akta.pro rank

Product category

Cannabinoid Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Cannabinoid therapeutics
• Liposomal drug delivery
• CBD wellness products
• Pharmaceutical pain management
• Veterinary pain therapeutics

Headquarters

HQ city

Herzliya

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Consumer Wellness Products: Revenue from sale of CBD-based personal care and beauty products through B.I. Sky Global subsidiary, including derma-cosmetic lines sold online and through retail distribution.
2. Pharmaceutical Development: Pre-commercial pharmaceutical pipeline development focusing on LPT-CBD for chronic pain management. Revenue will come from drug approval and commercialization once regulatory milestones are achieved.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

InnoCan Pharma develops proprietary CBD-based drug delivery platforms — notably the LPT-CBD liposome technology and a CBD-loaded exosome technology — for non-opioid chronic pain management in humans and animals. Through its wholly-owned B.I. Sky Global subsidiary, the company also develops and commercializes CBD-based personal care, derma-cosmetic, and topical wellness products via e-commerce and online marketplaces.

Product overview

Innocan Pharma is a dual-segment company operating in Pharmaceuticals and Consumer Wellness. In Pharmaceuticals, the core product is LPT-CBD (Liposome Platform Technology-Cannabidiol), an injectable sustained-release CBD delivery platform for non-opioid chronic pain management in both animals and humans. The Consumer Wellness segment is led by B.I. Sky Global subsidiary, a microbrands hub commercializing CBD wellness, derma-cosmetic, and personal care products. These segments share a common focus on cannabinoid-based drug delivery but serve different markets: pharmaceutical applications through LPT-CBD injections for chronic pain, and consumer products through topical formulations and beauty products.

Differentiator

Problem solved

Functional benefit

Brands

• B.I. Sky Global: Microbrands hub focused on advanced targeted online sales in personal care and beauty products
• LPT-CBD
• SHIR

Products and services

• LPT-CBD (Liposome Platform Technology-Cannabidiol) Injectable, sustained-release liposomal CBD therapeutic delivery system designed as a non-opioid treatment for chronic pain, osteoarthritis, and other conditions in humans and animals, providing up to four weeks of pain relief per injection.
• CBD Wellness Products (topical pain relief, derma-cosmetics, SHIR beauty line) Consumer wellness product line including topical pain relief formulations, derma-cosmetic products, and the SHIR CBD beauty brand distributed via e-commerce and retail partners in Canada, Italy, and Switzerland.
• Liposomal CBD Injection for Animal Health Veterinary pharmaceutical application of the LPT-CBD liposomal CBD platform targeting chronic pain conditions such as osteoarthritis in dogs through monthly injectable therapy.

Quantifiable outcome

• Significant pain reduction and improved wellbeing demonstrated in blinded crossover studies on osteoarthritic dogs
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core and minor.

• B.I. Sky Global Ltd.coreStrategic or Co-development PartnerJoint venture microbrands hub focusing on advanced targeted online sales of personal care and beauty products. Leverages unique capabilities to deliver and accelerate profitable growth in consumer wellness segment.
• Tel Aviv UniversityminorStrategic or Co-development PartnerResearch collaboration for CBD-based COVID-19 treatment development using exosome-loaded CBD technology.
• Endless SkyminorChannel Partner/ Reseller/ DistributorCalgary-based cannabis producer partnership for manufacturing and distribution of CBD products in Canada.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Teva Pharmaceutical Industries: Israel-based global generics and specialty pharma with established CNS and pain franchises; relevant as a country- and indication-overlapping incumbent for InnoCan's Israeli R&D base.
• Charlottes Web Holdings: Largest US hemp-derived CBD wellness brand; overlap with InnoCan's B.I. Sky Global consumer wellness segment and CBD beauty distribution.
• AbbVie: Owns leading chronic-pain franchises (e.g., Botox, Linzess) and a CNS/pain portfolio — the dominant incumbent InnoCan's LPT-CBD would compete against in non-opioid analgesia.

Emerging players

• Skye Bioscience: Clinical-stage cannabinoid pipeline (initially focused on glaucoma and metabolic health) — emerging comparable for InnoCan's expanding CBD therapeutic scope.
• Enveric Biosciences: Small-molecule cannabinoid-derived pipeline for CNS indications including anxiety and depression — comparable as an emerging cannabinoid CNS player.

Direct peers

• Zynerba Pharmaceuticals: Clinical-stage cannabinoid therapeutics developer focused on transdermal CBD for Fragile X, epilepsy, and developmental disorders — directly comparable as a small-cap CBD drug-delivery platform player.
• Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz acquired GW Pharmaceuticals, maker of Epidiolex — the only FDA-approved CBD therapeutic — making it the closest published peer for InnoCan's CBD drug-delivery thesis in chronic and CNS conditions.
• Corbus Pharmaceuticals: Develops cannabinoid-derived and related small molecules for inflammatory and fibrotic diseases — a directly overlapping cannabinoid therapeutic developer.
• Cardiol Therapeutics: Clinical-stage cannabinoid pharma focused on cannabidiol for inflammatory heart disease and acute myocarditis; relevant comparable as a small-cap CBD-pure-play with drug-delivery aspirations.

Others

• Tilray Brands: Diversified cannabis and CBD operator with consumer wellness, distribution, and pharma-adjacent operations spanning multiple geographies.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@InnoCanPharma
• LinkedInlinkedin.com/company/innocanpharma
• Xx.com/innocanp

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InnoCan Pharma